SFJ Pharmaceuticals

SFJ CEO Robert DeBenedetto

The biotech: SFJ Pharmaceuticals
Round: $21 million
Based: Pleasanton, CA
CEO: Robert DeBenedetto
Investors: Clarus Ventures, Undisclosed Investor

The scoop: Clarus was clearly drawn to SFJ's savvy business model. Gathering some professional drug developers together, the company has been executing deals for the clinical development of Big Pharma drugs specifically for Asian markets. SFJ just completed its second deal with Pfizer ($PFE) for a late-stage program for the lung cancer drug dacomitinib. That followed a deal on Pfizer's Inlyta (axitinib) and another one for Eisai's thyroid cancer drug lenvatinib. Great potential can't obscure the risks inherent in drug development, though, as Pfizer helped underscore recently with the news that Inlyta failed a late-stage test for kidney cancer. The miss, though, was close, which helped keep hope alive at Pfizer--and presumably SFJ.

For more:
Special Report: SFJ Pharmaceuticals - The Top 15 Biotech Venture Investments in H1 2012
Pfizer partners on lung cancer drug in deal to speed Asian development
Pfizer taps SFJ for cancer drug's Phase III


SFJ Pharmaceuticals

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.